The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

BACKGROUND: Atopic dermatitis (AD) is a chronically relapsing disease. Few biologics are approved for moderate-to-severe AD, and novel interventions are emerging. We aimed to evaluate the safety and efficacy of lebrikizumab, an IL-13 immunomodulator, as monotherapy vs. placebo in treating moderate-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashrahil, Bader, Alzahrani, Ziyad, Samarkandy, Sahal, Aman, Abdullah, Jfri, Abdulhadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884690/
https://www.ncbi.nlm.nih.gov/pubmed/36726353
http://dx.doi.org/10.3389/fmed.2022.1091271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884690/
https://www.ncbi.nlm.nih.gov/pubmed/36726353
http://dx.doi.org/10.3389/fmed.2022.1091271

Ejemplares similares